NIH Clinical Center: Search the Studies

Search the Studies

13 Studies found from all possible combinations of your search terms. Select a protocol that you wish to review.

Protocol Number	Title	Protocol Status	Min-Max Age	Institute	Keywords
000484-C	Randomized Phase II Trial of Durvalumab (D) plus Olaparib (O) and Cediranib (C: DOC) Compared to OC or DC or Chemotherapy in Platinum-Resistant Recurrent Ovarian Cancer with Prior Bevacizumab	Participants currently recruited/enrolled	18-125 Years	NCI	Conventional
21-C-0023	A Phase I Study of Pomalidomide and Nivolumab in Patients with Virus-Associated Malignancies With or Without HIV	Participants currently recruited/enrolled	18-125 Years	NCI	Leiomyosarcoma
20-C-0010	Phase II Trial of Radium-223 in Biochemically Recurrent Prostate Cancer	Participants currently recruited/enrolled	18-125 Years	NCI	Conventional
19-N-0081	A Traveling Subject Study of Replicability in Conventional and Advanced MRI MS Biomarkers	Completed Study; data analyses ongoing	18-125 Years	NINDS	Conventional
19-C-0016	Natural History and Biospecimen Acquisition Study for Children and Adults with Rare Solid Tumors	Participants currently recruited/enrolled	0-125 Years	NCI	Conventional
18-H-0011	Technical Development of Cardiovascular Magnetic Resonance Imaging (CMR) Using a Low Specific Absorption Rate (SAR) Scanner System	Participants currently recruited/enrolled	18-125 Years	NHLBI	Conventional
17-H-0118	A Phase II Study Of Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)	No longer recruiting/follow-up only	18-125 Years	NHLBI	Conventional
17-C-0012	A Phase I Study of a Combination of MM-398 and Veliparib in solid tumors	Completed Study; data analyses ongoing	18-125 Years	NCI	Conventional
09-H-0199	A Pilot Study of a Thrombopoietin-Receptor Agonist (TPO-R agonist), Eltrombopag, in Patients with Low to Int-2 Risk Myelodysplastic Syndrome (MDS)	Completed Study; data analyses ongoing	18-125 Years	NHLBI	Conventional
08-C-0130	A Phase II Trial of Peginterferon alfa-2b (PEG-Intron) for Neurofibromatosis Type 1 Related Unresectable, Symptomatic or Life-Threatening Plexiform Neurofibromas	Completed Study; data analyses ongoing	0-21 Years	NCI	Conventional
96-H-0100	Role of Genetic Factors in the Pathogenesis of Lung Disease	Participants currently recruited/enrolled	2-90 Years	NHLBI	Conventional
96-CH-0033	An Open, Randomized, Long-Term Clinical Trial of Flutamide, Testolactone, and Reduced Hydrocortisone Dose vs. Conventional Treatment of Children with Congenital Adrenal Hyperplasia	No longer recruiting/follow-up only	2-18 Years	NICHD	Conventional
94-DK-0127	Pathogenesis of Glomerulosclerosis	Completed Study; data analyses ongoing	2-125 Years	NIDDK	Conventional